Wave Life Sciences Reports Q2 2026 Financial Results and Clinical Progress
Wave Life Sciences (WVE) reported second-quarter financial results for 2026, showing revenue of $2.3 million driven by collaboration activities with GSK, a significant drop from the prior year's $8.7 million. The company recorded a net loss of $69.4 million compared to $50.5 million in Q2 2025 due to increased R&D and general administrative expenses. The firm maintains strong cash reserves of $490.6 million, which it expects will fund operations through the third quarter of 2028. Clinical progress includes promising data for WVE-007, with up to an 88% reduction in serum Activin E and a notable improvement in visceral fat-to-muscle ratio compared to semaglutide. Wave is advancing its pipeline across obesity, AATD, and PNPLA3 liver disease. The company also highlighted the potential for WVE-007 as an add-on therapy with GLP-1 drugs and plans to seek partnerships for Huntington's disease and Duchenne muscular dystrophy programs.
Topics: cash position clinical trials net loss R&D expenses revenue